Ousia Pharma

Ousia Pharma is a private, preclinical-stage biotech leveraging a proprietary peptide-drug conjugate platform to target appetite-controlling brain regions for the treatment of cardiometabolic diseases. The company boasts a strong founding team with deep expertise in neuroscience, metabolism, and medicinal chemistry, and is supported by a high-caliber board with significant industry and investment experience. While still in early development and pre-revenue, Ousia is positioned to address the massive, unmet need in obesity and related metabolic disorders with a potentially safer and more targeted approach than current therapies.

Peptide-drug conjugate (PDC) platform designed to deliver modulators of synaptic plasticity across the blood-brain barrier to specifically target appetite-controlling regions in the hypothalamus.

Ousia operates in the highly competitive obesity/cardiometabolic space, dominated by companies with GLP-1-based therapies (e.g., Novo Nordisk, Eli Lilly) and a pipeline of next-generation multi-agonists. Its primary differentiation is its brain-specific, synaptic plasticity-focused PDC platform, competing against other neuro-focused approaches but with a unique conjugate delivery strategy.